Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Mirum pharmaceuticals, inc. save search
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 0.85%
H: 1.21%
C: -0.44%
meeting liver pharmaceuticals
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-09-05 (Crawled : 14:00) - biospace.com/
TVTX | $5.745 -1.8% -1.83% 1.2M
|
Health Technology
|
| O: -1.08%
H: 2.24%
C: -3.54%
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 0.42%
H: 7.76%
C: 4.46%
rare liver treatment acquisition pharmaceuticals therapeutics
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
TVTX | $5.745 -1.8% -1.83% 1.2M
|
Health Technology
|
| O: 5.16%
H: 0.75%
C: -1.43%
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: -0.12%
H: 1.42%
C: 0.81%
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 1.18%
H: 7.3%
C: 2.18%
rare liver treatment pharmaceuticals acquire therapeutics agreement
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
Published: 2023-07-17 (Crawled : 12:00) - globenewswire.com
TVTX | $5.745 -1.8% -1.83% 1.2M
|
Health Technology
|
| O: 5.16%
H: 0.75%
C: -1.43%
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 1.18%
H: 7.3%
C: 2.18%
rare liver treatment pharmaceuticals therapeutics agreement
Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
Published: 2022-10-31 (Crawled : 21:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: -0.76%
H: 0.82%
C: -4.65%
liver meeting livmarli study
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
Published: 2022-10-27 (Crawled : 08:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 0.48%
H: 2.41%
C: -7.81%
rare liver disease
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
Published: 2022-06-24 (Crawled : 10:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: -0.15%
H: 1.07%
C: -8.91%
liver international
CORRECTING and REPLACING CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
Published: 2022-02-25 (Crawled : 09:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
can108 rare liver approval disease liver disease one ism syndros
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Published: 2021-09-21 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.35%
H: 0.58%
C: 0.06%
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 5.09%
H: 2.63%
C: 0.53%
disease liver disease liver license commercialization rare
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
Published: 2021-07-27 (Crawled : 05:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 4.99%
H: 0.37%
C: -11.88%
disease liver disease liver license commercialization rare
Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
Published: 2021-06-23 (Crawled : 16:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: -1.15%
disease liver disease liver rare
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
Published: 2021-06-16 (Crawled : 16:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: -0.22%
H: 2.67%
C: 0.28%
disease liver disease liver rare
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Published: 2021-04-29 (Crawled : 13:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K
|
Health Technology
|
| O: 3.37%
H: 0.0%
C: -7.79%
disease liver disease china liver license commercialization rare
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.